What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Cell-penetrating Wnt/Dishevelled-modulating peptide · hair-follicle research
Overview
PTD-DBM is a fusion peptide that couples a protein-transduction domain (a polyarginine cell-penetrating sequence) to a Dishevelled-binding motif. The DBM segment competes with the negative regulator CXXC5 for the PDZ domain of Dishevelled (Dvl); by displacing CXXC5 it lifts a brake on Wnt/β-catenin signaling, and because Wnt activation is central to hair-follicle neogenesis, PTD-DBM is studied as a research tool for hair-regeneration and wound-context Wnt biology. The polyarginine domain is what carries the otherwise membrane-impermeant motif into cells. PeptideXpo supplies PTD-DBM as a lyophilized powder at ≥ 98% HPLC. Its highly cationic arginine-rich domain governs handling: it is very water-soluble but binds readily to anionic surfaces and can complex with polyanions in buffer, so low-binding tubes and simple vehicles are preferred, and topical-model research often pairs it with a Wnt-activating small molecule (e.g. valproic acid) as reported in the source literature. Supplied in 1 mg fills as a research reference material only.
Who buys this, and why
Cosmetic-peptide buyers fall into two groups: established beauty / med-aesthetic brands extending an existing line, and OEM clients building a private-label catalog from scratch. The first group usually wants bulk active plus stability data in their existing carrier matrix; the second usually wants a finished formulation under their label. Both need INCI naming verified, regulator-specific safety files (CPNP for EU, FDA OTC monograph for US where relevant), and packaging-compatibility data.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
The Wnt/β-catenin pathway drives hair-follicle neogenesis, and CXXC5 acts as a negative feedback regulator by binding Dishevelled (Dvl) and dampening the signal. PTD-DBM's Dishevelled-binding motif competitively occupies the same site on Dvl, displacing CXXC5 and releasing the brake so Wnt signaling can proceed. The attached polyarginine transduction domain is what gets the peptide across the cell membrane to reach intracellular Dvl — this CXXC5-Dvl disruption mechanism is the basis for the hair-regeneration research interest.
Both act on the same pathway from different angles: PTD-DBM relieves CXXC5's inhibition of Dishevelled, while valproic acid is a GSK-3β-inhibiting Wnt activator. In the published hair-follicle work they are frequently combined for additive Wnt-pathway activation in topical models. Researchers reproducing that literature should note the co-treatment design rather than expecting PTD-DBM alone to match the combined-result data.
